Skip to main content
Premium Trial:

Request an Annual Quote

Merck May Eventually Own Up to 20 Percent of Genaissance in Pharmacogenomics Agreement

This article has been updated from a previous version.

NEW YORK, Sept. 24 (GenomeWeb News) - Merck may eventually own up to 19.9 percent of Genaissance as a  result of a license agreement between the companies in which Genaissance will use its haplotyping technology to develop a Merck antidepressant, said Genaissance CEO Kevin Rakin yesterday in a conference call. 

Genaissance hopes to develop and commercialize the selective seratonin inhibitor, called vilazodone, and will provide an upfront payment of about $1.2 million and milestone stock payments that may total another $43 million, payable in Genaissance common stock, said Rakin. "The vast majority of milestones are due at the time of the NDA filing," said Rakin in a conference call.

The agreement stipulates that Merck cannot own more than a 19.9 percent share of Genaissance stock.

Merck will receive royalties from the drug and any accompanying diagnostic test, said Rakin during the conference call.

During the first half of 2005, Genaissance hopes to begin enrollment for a Phase II clinical trial that will include pharmacogenomic characterization of patients, said a Merck statement yesterday.  

Vilazodone is also a 5HT1A partial agonist, said Merck.  In Phase II clinical trials for depression, the compound has shown signals of efficacy and a favorable side effects profile in more than 1,000 patients, the company added.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.